+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Characterization of the molecular forms of immunoreactive parathyroid hormone in primary hyperparathyroidism and in hyperparathyroidism due to renal failure



Characterization of the molecular forms of immunoreactive parathyroid hormone in primary hyperparathyroidism and in hyperparathyroidism due to renal failure



Scandinavian Journal of Clinical and Laboratory Investigation 43(7): 553-564



Radioimmunological determination of immunoreactive parathyroid hormone (iPTH) in sera of patients with primary and secondary hyperparathyroidism was carried out using antisera specific for the amino-terminal and the mid-region part of the hormone. In 58 patients with primary hyperparathyroidism and in 29 patients with the secondary form of the disease due to renal failure, there was a linear correlation between the concentration of serum iPTH determined with the two types of antiserum. In all cases the mid-region-specific antiserum measured the highest iPTH concentrations. The molecular forms of serum iPTH were examined after gel filtration of Sephadex G-75 followed by Bio-Gel P-60 in nine patients. Fractions which represented molecular forms equal to or smaller than intact PTH were collected. Using the mid-region-specific antiserum, the predominant immunoreactivity (50-80%) eluted corresponding to one or several large fragments in both forms of the disease. In contrast, iPTH activity co-eluting with the intact hormone represented 2-8% of the total. Similar elution profiles were observed when the amino-terminal-specific radioimmunoassay was used. However, this antiserum showed that in both disease states relatively higher concentrations of iPTH co-eluted with the intact hormone (about 20%). In conclusion, the higher serum iPTH concentrations measured with mid-region-specific antiserum are mainly due to quantitative differences due to the presence of large and intermediate sized fragments. The appearance of higher concentrations of iPTH in secondary hyperparathyroidism may be due to a reduced degradation and/or filtration by the kidney.

(PDF emailed within 0-6 h: $19.90)

Accession: 042516000

Download citation: RISBibTeXText

PMID: 6658372

DOI: 10.1080/00365518309168832


Related references

Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure. Brazilian Journal of Medical and Biological Research 34(12): 1547-1550, 2001

Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. Journal of Clinical Investigation 54(1): 175-181, 1974

Failure of cimetidine to suppress immunoreactive parathyroid hormone and hypercalcaemia in primary hyperparathyroidism. Postgraduate Medical Journal 57(666): 242-243, 1981

Cimetidine and primary hyperparathyroidism: failure of reduction of blood levels of parathyroid hormone in 5 cases of primary hyperparathyroidism. La Clinica Terapeutica 98(1): 63-68, 1981

Circulating molecular forms of parathyroid hormone in primary and secondary hyperparathyroidism. Brazilian Journal of Medical and Biological Research 22(8): 963-965, 1989

Failure of H2-receptor antagonists to affect serum calcium and immunoreactive parathyroid hormone levels in normal subjects and patients with primary hyperparathyroidism. Netherlands Journal of Medicine 26(6): 149-152, 1983

Effect of renal function on renal responsiveness to parathyroid hormone in primary hyperparathyroidism and chronic renal failure. European Journal of Clinical Investigation 15(1): 38-44, 1985

Studies of the half-life of plasma parathyroid hormone: rate of disappearance of immunoreactive fragments of the hormone after surgical removal of the parathyroid adenoma in primary hyperparathyroidism. Bollettino Della Societa Italiana di Biologia Sperimentale 55(7): 640-646, 1979

Tertiary hyperparathyroidism after renal transplantation--report of two cases and comparative study of parathyroid function with secondary hyperparathyroidism in chronic renal failure. Transplantation Proceedings 26(4): 2167-2169, 1994

Response of immunoreactive parathyroid hormone to intravenous phosphate infusion in primary hyperparathyroidism. Klinische Wochenschrift 52(1): 30-32, 1974

Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. Journal of Hypertension 34(9): 1778-1786, 2017

Reelevation of parathyroid hormone level after parathyroidectomy in patients with primary hyperparathyroidism: importance of decreased renal parathyroid hormone sensitivity. Surgery 137(4): 419-425, 2005

Renal electrolyte excretion in urolithiasis with special consideration of primary hyperparathyroidism. IV. Comparative studies in patients with primary hyperparathyroidism before and following parathyroid adenoma extirpation. Der Urologe 6(3): 176-184, 1967

Effect of cimetidine on serum immunoreactive parathyroid hormone in primary hyperparathyroidism and in chronic hemodialysis patients. Taiwan Yi Xue Hui Za Zhi. Journal of the Formosan Medical Association 82(12): 1216-1222, 1983

Improved diagnosis of primary hyperparathyroidism by defining the inverse relationship between serum immunoreactive parathyroid hormone and calcium. Scandinavian Journal of Clinical & Laboratory Investigation 46(5): 435-442, 1986